|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berasain C, Castillo J, Perugorria MJ,
Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer:
New molecular links. Ann N Y Acad Sci. 1155:206–221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leng J, Han C, Demetris AJ, Michalopoulos
GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma
cell growth through Akt activation: Evidence for Akt inhibition in
celecoxib-induced apoptosis. Hepatology. 38:756–768. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H,
Jiang J, Chen J, Chen G and Wu B: β-Arrestin1 enhances
hepatocellular carcinogenesis through inflammation-mediated Akt
signalling. Nat Commun. 6:73692015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uegaki K, Kanamori Y, Kigawa J, Kawaguchi
W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H
and Terakawa N: PTEN-positive and phosphorylated-Akt-negative
expression is a predictor of survival for patients with advanced
endometrial carcinoma. Oncol Rep. 14:389–392. 2005.PubMed/NCBI
|
|
8
|
Hager M, Haufe H, Kemmerling R, Hitzl W,
Mikuz G, Moser PL and Kolbitsch C: Increased activated Akt
expression in renal cell carcinomas and prognosis. J Cell Mol Med.
13:2181–2188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malinowsky K, Nitsche U, Janssen KP, Bader
FG, Späth C, Drecoll E, Keller G, Höfler H, Slotta-Huspenina J and
Becker KF: Activation of the PI3 K/AKT pathway correlates with
prognosis in stage II colon cancer. Br J Cancer. 110:2081–2089.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tokunaga E, Kimura Y, Oki E, Ueda N,
Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H and
Maehara Y: Akt is frequently activated in HER2/neu-positive breast
cancers and associated with poor prognosis among hormone-treated
patients. Int J Cancer. 118:284–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai DL, Martinka M and Li G: Prognostic
significance of activated Akt expression in melanoma: A
clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang W, Wen Q, Xu L, Xie G, Li J, Luo J,
Chu S, Shi L, Huang D, Li J and Fan S: Activation of Akt/mTOR
pathway is associated with poor prognosis of nasopharyngeal
carcinoma. PLoS One. 9:e1060982014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Guo X, Yang M, Yu L, Li Z and Lin
N: Identification of AKT kinases as unfavorable prognostic factors
for hepatocellular carcinoma by a combination of expression
profile, interaction network analysis and clinical validation. Mol
Biosyst. 10:215–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gedaly R, Angulo P, Chen C, Creasy KT,
Spear BT, Hundley J, Daily MF, Shah M and Evers BM: The role of
PI3K/mTOR inhibition in combination with sorafenib in
hepatocellular carcinoma treatment. Anticancer Res. 32:2531–2536.
2012.PubMed/NCBI
|
|
15
|
Simioni C, Martelli AM, Cani A,
Cetin-Atalay R, McCubrey JA, Capitani S and Neri LM: The AKT
inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying
hyperphosphorylated AKT-1 and synergizes with conventional
chemotherapy. Oncotarget. 4:1496–1506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu
B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses
the acquired resistance to sorafenib by switching protective
autophagy to autophagic cell death in hepatocellular carcinoma. Mol
Cancer Ther. 13:1589–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu HC, Hung MH, Chen YL, Chu PY, Wang CY,
Chao TT, Liu CY, Shiau CW and Chen KF: Erlotinib derivative
inhibits hepatocellular carcinoma by targeting CIP2A to reactivate
protein phosphatase 2A. Cell Death Dis. 5:e13592014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahmad SA, Bilimoria MM, Wang X, Izzo F,
Delrio P, Marra P, Baker TP, Porter GA, Ellis LM, Vauthey JN, et
al: Hepatitis B or C virus serology as a prognostic factor in
patients with hepatocellular carcinoma. J Gastrointest Surg.
5:468–476. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Oliveria Andrade LJ, D'Oliveira A, Melo
RC, De Souza EC, Silva Costa CA and Paraná R: Association between
hepatitis C and hepatocellular carcinoma. J Glob Infect Dis.
1:33–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Douam F, Ding Q and Ploss A: Recent
advances in understanding hepatitis C. F1000Res. 3(5): pii: F1000
Faculty Rev. –131. 2016.
|
|
22
|
Street A, Macdonald A, Crowder K and
Harris M: The Hepatitis C virus NS5A protein activates a
phosphoinositide 3-kinase-dependent survival signaling cascade. J
Biol Chem. 279:12232–12241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Street A, Macdonald A, McCormick C and
Harris M: Hepatitis C virus NS5A-mediated activation of
phosphoinositide 3-kinase results in stabilization of cellular
beta-catenin and stimulation of beta-catenin-responsive
transcription. J Virol. 79:5006–5016. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Tian Y, Machida K, Lai MM, Luo G,
Foung SK and Ou JH: Transient activation of the PI3K-AKT pathway by
hepatitis C virus to enhance viral entry. J Biol Chem.
287:41922–41930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ali N, Allam H, May R, Sureban SM, Bronze
MS, Bader T, Umar S, Anant S and Houchen CW: Hepatitis C
virus-induced cancer stem cell-like signatures in cell culture and
murine tumor xenografts. J Virol. 85:12292–12303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gargini R, Cerliani JP, Escoll M, Antón IM
and Wandosell F: Cancer stem cell-like phenotype and survival are
coordinately regulated by Akt/FoxO/Bim pathway. Stem Cells.
33:646–660. 2015. View Article : Google Scholar : PubMed/NCBI
|
